BHVN vs ZYME: Which Stock Is the Better Buy?
Biohaven Ltd. and Zymeworks Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BHVN vs ZYME, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Biohaven Ltd. (BHVN) | Zymeworks Inc. (ZYME) | |
|---|---|---|
| Market cap | $1.7B | $1.7B |
| Revenue (latest FY) | $0 | $105.97M |
| Net income (latest FY) | $-738.82M | $-81.13M |
| Revenue growth (5y CAGR) | — | 22.2% |
| Net margin | — | -76.6% |
| Return on equity | -1418.8% | -30.2% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full BHVN vs ZYME breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BHVN's full financials → Open ZYME's full financials →More comparisons
Frequently asked questions
Which is bigger, BHVN or ZYME?
Zymeworks Inc. is larger by market capitalization — $1.7B versus $1.7B.
Which grows faster, BHVN or ZYME?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
BHVN fundamentals → · ZYME fundamentals → · All 1,500+ companies → · Free screener →